.jpg?format=webp&width=780)
A study involving 7,102 patients compared the treatment patterns of three anti-inflammatory agents: Cyclosporine ophthalmic solution 0.09% (CEQUA®, OTX-101), cyclosporine ophthalmic emulsion 0.05% (Restasis®), and lifitegrast ophthalmic solution 5% (Xiidra®), for Dry Eye Disease (DED) patients. The study OTX-101 outperforms the other two, with patients staying on the treatment longer and less likely to discontinue. Older patients, in particular, benefited from OTX-101. These findings shed light on the distinct treatment patterns for DED patients.
Like
Save
Share